General

Presentation at the Locust Walk Stem Cell Tx Conference

Dr Ian Nisbet Chief Operating Officer

Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited […]

2022-04-08T11:41:15+10:00April 8th, 2022|

7th Innate Killer Summit 2022, Dr Nicholas Boyd Presenting

7th Innate Killer Summit (San Diego, California)

Cartherics Chief Development Officer, Dr Nicholas Boyd

The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment. From 30 March-1 April 2022 Pacific Daylight Time (PDT) industry experts will meet in San Diego, California to discuss […]

2022-04-01T18:33:22+11:00March 25th, 2022|

The 4th Allogeneic Cell Therapies Summit is the leading industry-dedicated meeting that considers pre-clinical developmenttranslationmanufacturingsupply and storage of allogeneic cell therapies to improve the accessibility and efficacy of patient care worldwide.

400+ experts from pharma, biotech and leading academia are expected to attend in Boston, USA […]

2022-03-04T14:28:58+11:00March 4th, 2022|

Presentation at the Next Generation CAR-TCR Summit (London, UK)

Presentation at the Next Generation CAR-TCR Summit (London, UK)

Cartherics Chief Development Officer, Dr Nicholas Boyd

CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing […]

2022-03-08T18:59:41+11:00February 23rd, 2022|

Presentation: Multi-Functional Cell Therapies Summit

Chief Development Officer, Dr Nicholas Boyd

Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.

On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]

2022-01-27T16:58:33+11:00January 27th, 2022|

The Right Time & The Right Place

Cartherics welcomes a new Senior Research Fellow who says she has finally found The Right Job

By Leigh Dayton, 20 January 2022

Pollyanna Goh – Polly to her friends, family and colleagues – is a specialist’s specialist. For the past decade she has worked in the field of induced pluripotent stem cells (iPSCs). She was such an […]

2022-01-20T10:36:47+11:00January 20th, 2022|

‘Off-the-Shelf’ Immunotherapy Gets Special Treatment in Special Issue of The Journal Cells

Thanks go to Special Editor, Cartherics CEO Alan Trounson

By Leigh Dayton, 17 January 2022

Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.

This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]

2022-01-17T09:29:18+11:00January 17th, 2022|

A Star is Born! Cartherics student takes out top award …..

By Leigh Dayton,  4 January 2022

When Cartherics Biomedical Honours student Elizabeth (Liz) Bakaniozos opened an e-mail this month from the Director and CEO of Monash University’s Hudson Institute of Medical Research she was “really surprised and grateful”.

And rightly so. Elizabeth Hartland wrote to advise and congratulate Liz on winning the Hudson Institute Lois Salamonsen Honours […]

2022-01-04T12:17:29+11:00January 4th, 2022|
Go to Top